Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (MODULATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03647839
Recruitment Status : Completed
First Posted : August 27, 2018
Last Update Posted : August 27, 2021
Sponsor:
Information provided by (Responsible Party):
Australasian Gastro-Intestinal Trials Group

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 29, 2021
Actual Study Completion Date : April 9, 2021